FN-1501通过诱导细胞循环停止和亡来抑制扩散性大B细胞淋巴瘤瘤的生长
Dan Zou1, Bowen Hu1, Sitong Feng1
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
Anti-cancer agents in medicinal chemistry
|September 4, 2024
概括
FN-1501通过诱导细胞循环停止和亡,有效地抑制扩散性大B细胞淋巴瘤 (DLBCL) 细胞生长和存活. 这种新型治疗剂在治疗复发性或耐火性DLBCL方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有高治疗耐药性和复发率的侵袭性癌症.
- 标准化疗在30-50%的DLBCL患者中是无效的,需要新的治疗策略.
- FN-1501是一种双重抑制剂,向循环素依赖激酶和FMS类受体氨酸激酶3.
研究的目的:
- 在DLBCL模型中研究FN-1501的抗瘤疗效.
- 阐明FN-1501抗癌作用背后的分子机制.
- 评估FN-1501作为耐火/复发DLBCL的治疗选择的潜力.
主要方法:
- 在体外研究中使用了细胞计数kit-8测定,西部涂抹和流动细胞计量来评估增殖,细胞循环和细胞亡.
- 在体内有效性使用DLBCL异种移植瘤模型进行了评估.
- 进行了信号通路分析 (MAPK,PI3K/AKT/mTOR) 和救援研究.
主要成果:
- 在实验室中,FN-1501证明了DLBCL细胞增殖的剂量和时间依赖的抑制.
- FN-1501诱导G1/S阶段细胞周期停止和卡斯帕酶依赖的细胞灭绝.
- 在体内,FN-1501显著降低了瘤体积和体重,延长了无进展的生存期.
- FN-1501抑制了MAPK和PI3K/AKT/mTOR通路,这些通路介于细胞循环停止和细胞亡.
结论:
- 在体外和体外模型中,FN-1501对DLBCL表现出显著的抗瘤活性.
- 药物的机制包括抑制关键细胞生存途径 (MAPK,PI3K/AKT/mTOR).
- FN-1501代表了一种潜在的新治疗药物,用于复发性或耐火性DLBCL的患者.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.2K
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
5.9K
相关概念视频
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
